Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled trial of efgartigimod in adults with primary membranous nephropathy in China
CTR20223159Phase 2Terminated
- Sponsor
- argenx
- Start
- Dec 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of efgartigimod alfa in idiopathic membranous glomerulonephritis (IMG), sponsored by argenx. Started Dec 2022; status: terminated.
02
Drugs
efgartigimod alfa
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on CTR20223159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223159.